Key Points
- ACADIA EVP Mark Schneyer sold 5,849 shares for approximately $169,621 at an average price of $29.00, reducing his ownership by 7.94%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- ACADIA reported quarterly EPS of $0.18 versus the $0.07 analyst consensus and revenue of $308 million, up 16.4% year over year and above expectations. Shares were trading up 2.7% at $29.21.
- Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $33.44; several firms recently raised their targets, including Citizens JMP and Canaccord Genuity to $36.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark Schneyer sold 5,849 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $29.00, for a total transaction of $169,621.00. Following the sale, the executive vice president owned 67,828 shares of the company's stock, valued at approximately $1,967,012. The trade was a 7.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ACADIA Pharmaceuticals Trading Up 2.7%
Shares of NASDAQ:ACAD opened at $29.21 on Friday. The stock has a market capitalization of $5.03 billion, a P/E ratio of 13.16, a price-to-earnings-growth ratio of 16.74 and a beta of 0.81. The stock's 50-day moving average price is $24.39 and its 200-day moving average price is $23.27. ACADIA Pharmaceuticals Inc. has a 12-month low of $19.69 and a 12-month high of $29.48.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $0.11. The company had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.ACADIA Pharmaceuticals's revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.16 EPS. As a group, research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.46 EPS for the current year.
Analyst Ratings Changes
ACAD has been the topic of several analyst reports. Citigroup reaffirmed a "market outperform" rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday. Stifel Nicolaus raised their price target on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a "hold" rating in a report on Tuesday, July 21st. HC Wainwright restated a "buy" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday. Citizens Jmp upped their price objective on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the company a "market outperform" rating in a research note on Wednesday. Finally, Canaccord Genuity Group increased their target price on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $33.44.
Check Out Our Latest Research Report on ACAD
More ACADIA Pharmaceuticals News
Here are the key news stories impacting ACADIA Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
- Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
- Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
- Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
- Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
- Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update
Institutional Trading of ACADIA Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ACAD. Farther Finance Advisors LLC boosted its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 386 shares in the last quarter. Meeder Asset Management Inc. bought a new position in ACADIA Pharmaceuticals in the 4th quarter worth $26,000. Transamerica Financial Advisors LLC raised its holdings in ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 1,005 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company's stock worth $43,000 after purchasing an additional 1,185 shares during the period. Finally, Leonteq Securities AG purchased a new stake in shares of ACADIA Pharmaceuticals in the 4th quarter worth about $52,000. Hedge funds and other institutional investors own 96.71% of the company's stock.
About ACADIA Pharmaceuticals
(
Get Free Report)
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company's flagship product, NUPLAZID® (pimavanserin), received U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
